What is the recommended treatment regimen for mast cell activation syndrome?

Treatment of Mast Cell Activation Syndrome

The cornerstone of MCAS treatment is prophylactic therapy with H1 and H2 antihistamines, often at higher-than-standard doses, combined with acute management using epinephrine auto-injectors for patients with a history of anaphylaxis. 1

First-Line Prophylactic Therapy

Antihistamine Regimen

• Start with second-generation H1 antihistamines (fexofenadine or cetirizine) at 2-4 times FDA-approved doses to reduce dermatologic manifestations (flushing, pruritus), tachycardia, and abdominal discomfort 1
• Add H2 receptor blockers (famotidine or cimetidine) to treat abdominal and vascular symptoms, as they prevent histamine-mediated acid secretion and blunt vasoactive effects when combined with H1 antagonists 1
• Antihistamines work better as prophylaxis than acute treatment because once symptoms appear, histamine has already bound to receptors 1

Critical caveat: Avoid first-generation H1 antihistamines (diphenhydramine, hydroxyzine) in elderly patients due to cognitive decline risk from anticholinergic effects, particularly concerning in MCAS patients prone to cardiovascular events 1

Stepwise Escalation for Refractory Symptoms

Second-Line Agents

• Leukotriene modifiers (montelukast) or 5-lipoxygenase inhibitors (zileuton) for bronchospasm or gastrointestinal symptoms, particularly if urinary LTE4 levels are elevated 1, 2
• Cyproheptadine for gastrointestinal symptoms (diarrhea, nausea) due to dual H1 and serotonin receptor antagonism 1
• Ketotifen (compounded tablets) for dermatologic, gastrointestinal, and neuropsychiatric symptoms, though evidence of superiority over other antihistamines is unproven 1

Third-Line Options

• Omalizumab has shown efficacy in preventing anaphylactic episodes in MCAS patients, with case reports demonstrating sustained clinical response even at low doses (150 mg monthly) 1, 3
• Short-term corticosteroids (prednisone 0.5 mg/kg/day) with slow taper over 1-3 months for refractory symptoms, though long-term use is limited by side effects 1
• Prophylactic prednisone (50 mg at 13,7, and 1 hour before procedures) when mast cell activation has been problematic during radiologic or invasive procedures 1

Acute Episode Management

Immediate Interventions

• Epinephrine auto-injector is mandatory for all patients with history of systemic anaphylaxis or airway angioedema 1, 4
• Supine positioning immediately for those with recurrent hypotensive episodes, using bedpan for diarrhea and emesis basin after rolling to side 1
• Albuterol via nebulizer or metered-dose inhaler for bronchospasm symptoms 1

Emerging Therapies

Novel Targeted Approaches

• Tyrosine kinase inhibitors (avapritinib, midostaurin) are being investigated for severely affected, therapy-refractory patients, though primarily studied in systemic mastocytosis rather than MCAS 5
• Lirentelimab (anti-Siglec-8 antibody) shows promise in indolent systemic mastocytosis and may have future applications in MCAS 5

Treatment Algorithm Summary

1. Initiate H1 antihistamine (cetirizine/fexofenadine at 2-4× standard dose) + H2 blocker (famotidine) 1
2. Prescribe epinephrine auto-injector if anaphylaxis history exists 1, 4
3. Add leukotriene modifier if bronchospasm or GI symptoms persist 1
4. Consider cyproheptadine for refractory GI symptoms 1
5. Trial omalizumab for recurrent anaphylaxis despite maximal antihistamine therapy 1, 3
6. Reserve corticosteroids for severe refractory cases, using shortest duration possible 1

Important pitfall: Elevated baseline serum tryptase or urinary mediators are not diagnostic of MCAS, nor do normal values exclude it—diagnosis requires acute elevation during episodes compared to baseline 4. Treatment decisions should be based on clinical presentation and response to therapy, not baseline mediator levels alone 6, 4.